ReviewOncogene2009
Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones.
Review in Oncogene, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Cancer-derived extracellular succinate: a driver of cancer metastasis.Journal of biomedical science · 2022Review
- Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance.Cells · 2022Review
- Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide.Experimental and therapeutic medicine · 2021Article
- Inhibitors of theCells · 2021Review
- Identifying intracellular signaling modules and exploring pathways associated with breast cancer recurrence.Scientific reports · 2021Article
- Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1.Experimental & molecular medicine · 2020Article
- Heat Shock Proteins in Glioblastoma Biology: Where Do We Stand?International journal of molecular sciences · 2019Review
- The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease.International journal of molecular sciences · 2018Review
- Profiles of Radioresistance Mechanisms in Prostate Cancer.Critical reviews in oncogenesis · 2018Review
- Hsp90 inhibitors as senolytic drugs to extend healthy aging.Cell cycle (Georgetown, Tex.) · 2018Review
- Bypassing Mechanisms of Mitochondria-Mediated Cancer Stem Cells Resistance to Chemo- and Radiotherapy.Oxidative medicine and cellular longevity · 2016Review
- Comparative Study of 17-AAG and NVP-AUY922 in Pancreatic and Colorectal Cancer Cells: Are There Common Determinants of Sensitivity?Translational oncology · 2014Article
- Mitochondrial oxidative phosphorylation TRAP(1)ped in tumor cells.Trends in cell biology · 2014Review
- Combination treatment with doxorubicin and gamitrinib synergistically augments anticancer activity through enhanced activation of Bim.BMC cancer · 2014Article
- The mitochondrial permeability transition pore and cancer: molecular mechanisms involved in cell death.Frontiers in oncology · 2014Review
- Structural bioinformatics and protein docking analysis of the molecular chaperone-kinase interactions: towards allosteric inhibition of protein kinases by targeting the hsp90-cdc37 chaperone machinery.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1.Molecular oncology · 2013Article
- Hsp90 regulation of mitochondrial protein folding: from organelle integrity to cellular homeostasis.Cellular and molecular life sciences : CMLS · 2013Article
- The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase.Cell metabolism · 2013Article
- Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.Current molecular medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
There is a plethora of attractive drug targets in cancer, but their therapeutic exploitation proved more difficult than expected, and only rarely truly successful. One possibility not often considered in drug discovery is that cancer signaling pathways are not randomly arranged in cells, but orchestrated in specialized subcellular compartments. The identification of heat shock protein-90 (Hsp90) chaperones in mitochondria of tumors, but not most normal tissues, provides an example of a compartmentalized network of cell survival, opening fresh prospects for novel, subcellularly targeted cancer drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.